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Scope: The Optimal Fibre Trial (OptiFiT) investigates metabolic effects of
insoluble cereal fibre in subjects with impaired glucose tolerance (IGT),
showing moderate glycemic and anti-inflammatory benefits, especially in
subjects with an obesity-related phenotype. An OptiFiT sub-group is analysed
for effects on body fat distribution.
Methods and results: 180 participants with IGT receive a blinded,
randomized supplementation with insoluble cereal fibre or placebo for 2
years. Once a year, all subjects undergo fasting blood sampling, oral glucose
tolerance test, and anthropometric measurements. A subgroup (n=47) also
received magnetic resonance imaging and spectroscopy for quantification of
adipose tissue distribution and liver fat content. We compared MR, metabolic
and inflammatory outcomes between fibre and placebo group metabolism
and inflammation.
Visceral and non-visceral fat, fasting glucose, HbA1c, fasting insulin, insulin
resistance, and uric acid decrease only in the fibre group, mirroring effects of
the entire cohort. However, after adjustment for weight loss, there are no
significant between-group differences. There is a statistical trend for
fibre-driven liver fat reduction in subjects with confirmed non-alcoholic fatty
liver disease (NAFLD; n = 19).
Conclusions: Data and evidence on beneficial effects of insoluble cereal fibre
on visceral and hepatic fatstorage is limited, but warrants further research.
Targeted trials are required.
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1. Introduction
The systemic metabolic disorder of type
2 diabetes mellitus (T2DM) is a systemic
burden of modern societies and health
care systems. The rising case numbers
will soon be followed by an increase in
comorbidities, invalidity and premature
deaths in most countries of the world.
This perspective is not unavoidable, as
T2DMonset and progression are strongly
influenced by lifestyle factors such as en-
ergy balance and specific dietary compo-
nents. By addressing these factors in a
structured prevention setting, T2DM in-
cidence can be reduced by about 50%.[1–4]
More than 60% of T2DM patients are
obese, most of them with visceral adipos-
ity. Also up to 75% of T2DM patients are
diagnosed with non-alcoholic fatty liver
disease (NAFLD).[5] Similar prevalences
apply to prediabetes.[6] These fat depots
independently increase long-term mor-
bidity for these patients.[7] Thus, sim-
ply reducing food intake may lead to di-
abetes remission, but given discussions
about the obesity paradox and limited
compliance to dietary restrictions it is still
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unclear how feasible a general approach of fasting techniques or
very-low calorie dietsmight actually be. Despite achieving normal
glucose regulation by losing weight, several side effects and the
large proportion of primarily non-obese T2DM patients need to
be taken into account.
Apart from overnutrition, specific nutritional factors such as
saturated fats, alcohol, and insoluble dietary fibre contribute to
the dietary risk profile for T2DM.[8] However, these factors, too,
are hard to modulate in a long-term perspective for most of the
subjects. Also, up to now, these factors are merely described as
risk-associated on the basis of cohort studies, while interven-
tional data is limited. The impressive risk reduction by high in-
take of insoluble cereal fibre has recently been addressed by the
first long-term randomized controlled trial (RCT)—the Optimal
Fibre trial (OptiFiT). It demonstrated small-to-moderate dose-
dependent effects on 2-h glucose and HbA1c levels as well as on
an inflammatory outcome.[9,10] In subjects with combined im-
paired fasting glucose (IFG) and glucose intolerance, a pheno-
type linked to both obesity and NAFLD, glycemic improvements
were stronger than in subjects with isolated impaired glucose tol-
erance (IGT).[11] Stratification by obesity did not show a relevant
effect-modulation for glycemic improvements, but for reductions
in leukocyte count, a measure for systemic inflammation.[12]
Dose-dependent analysis of the trial corroborated these findings
and underlined a potential involvement of liver fat reduction in
the overall metabolic amelioration.[10]
Insoluble cereal fibre is typically poorly fermentable; there-
fore, production of small-chain fatty acids in the gut is unlikely
to play an important mechanistic role for this type of dietary
fibre.[13,14] Still, high intake of insoluble cereal fibre is associ-
ated with a reduced risk for NAFLD, showing stronger effect
sizes than fruit and vegetable fibre, both of which are mainly
soluble.[15,16] While there is not a single human RCT, specifically
investigating the effect of insoluble dietary fibre on liver fat,
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there is at least some preclinical evidence for such effects in
rats.[17] In humans, subjects with higher intake of insoluble
fibre have smaller visceral adipose tissue depots.[18,19] Also,
whole grain intake seems to actively reduce inflammation and
abdominal body fat, irrespective of weight loss.[20] However, this
could be related to various whole grain components, includ-
ing proteins, minerals, vitamins and different types of fibre.
Once again, up to now there is also no publication on specific
effects of insoluble cereal fibre on visceral fat. Previous rodent
studies using cellulose supplements did not show a reduction
in visceral fat mass, but anti-inflammatory changes in the gut
microbiome.[21,22]
In all previous assessments within OptiFiT, surrogate mea-
sures for visceral fat—waist circumference or waist-to-hip ratio—
and NAFLD—fatty liver index (FLI) or other scores—were used,
considering their limitation especially in longitudinal studies.[23]
However, a subgroup of the OptiFiT cohort underwent a detailed
study protocol including magnetic resonance imaging and spec-
troscopy (MRI/MRS), providing precise data on body fat distribu-
tion and liver fat content. Based on these data, we want to clarify
the involvement of pathological fat depots in the glycemic im-
provements by supplementationwith specifically insoluble cereal
fibre as the first clinical study so far.
2. Research Design and Methods
The study protocol was approved by the ethics committee of the
University of Potsdam as well as the ethics committee of the
Charité, and all individuals gave written informed consent. The
trial was registered at clinicaltrials.gov (NCT 01681173). In our
previous core paper, we already reported the details for ethics
approval, study registration and recruitment, documented the
inclusion and exclusion criteria and described the overall study
design.[9] 180 subjects with IGT were recruited. This metabolic
subtype of prediabetes was chosen, as it bears an elevated risk for
diabetes onset and long-term complications.[24] Major metabolic
outcomes were assessed once a year, including fasting blood
sampling, oral glucose tolerance test, and anthropometric mea-
surements. A subgroup of the cohort (n = 47) also received MRI
and MRS according to previously defined protocols. Subjects
with and without MR examination did not differ from each other
with respect to sex, age, BMI, or glycemic state. Selection for MR
examination was done in a randomized fashion before allocation
to the intervention groups. Subjects with and without MR data
received the same intervention. 28 of the subjects with MR data
completed the first year of intervention, which consisted of the
supplementation and the modified lifestyle intervention pro-
gram PREDIAS.[25] The 12 consultations focused on increased
physical activity (240 min week−1) and on dietary recommen-
dations of the German Society for Nutrition (DGE): Fat intake
< 30 kcal%, intake of saturated fat < 10 kcal%, intake of total
dietary fibre > 15 g/1000 kcal. Dietary fibre should be gained
from whole-grain products, legumes, vegetables, and low-sugar
fruits such as berries. Low-fat dairy and meat products, soft
margarines, and healthy vegetable oils were recommended to
sustain a low-fat profile.
Dietary baseline status and interventional compliance was
assessed by 4-day food records. Nutrient intake, including
all macro- and several micronutrients, was determined using
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the nutrition software PRODI 5.8 based on Bundeslebensmit-
telschlüssel 3.0.[26]
2.1. Dietary Supplement
Details on the supplementation procedure, measurements and
laboratory parameters have been given in the core paper.[9]
Patients’ adherence to the supplementation was controlled by
weighing the frequently returned supplement tins after each dis-
pension period.
2.2. Calculations
Insulin resistancewas assessed by the homeostasismodel assess-
ment homeostasis model assessment insulin resistance index[27]
and the insulin sensitivity index of blood free fatty acids[28] as well
as the dynamic insulin sensitivity index by Belfiore.[29] We also as-
sessed the hepatic insulin clearance according to the established
formula.[30]
In order to mirror findings of the entire cohort, we also report
the FLI in addition to MR results.[31]
2.3. Statistical Analyses
In order to provide parallel data to the core publication, this analy-
sis was done by intention-to-treat principles, as well. Missing data
was filled by the last-observation-carried-forward method, there-
fore both completers and non-completers are included. We used
the Kolmogorov-Smirnov test in order to determine normal dis-
tribution of our data. Given the frequent absence of normal distri-
bution, we decided to conduct non-parametric tests throughout
the entire trial ensuring a uniform representation of our data.
We used Mann–Whitney tests for cross-sectional comparisons
andWilcoxon tests for longitudinal comparisons. All data are pre-
sented as means ± standard deviation. The results were consid-
ered significantly different if p< 0.05. All statistical analyses were
performed using SPSS forWindows program version 22.0 (SPSS
Inc, Chicago, IL, USA).
3. Results
Baseline data for this sub-cohort is given in Table 1. There are no
differences between fibre and placebo group.
Baseline and interventional state of dietary intake are shown in
Table 2. While there were no differences before the intervention,
intake of total (and in particular: insoluble) fibre was significant
higher in the fibre group.
Interventional changes are presented in Table 3. Within the
placebo group, body weight was the only variable with a sig-
nificant decrease, while in the fibre group, anthropometric,
glycemic, and other metabolic parameters improved signifi-
cantly. While there was no significant difference in change of
body weight between the groups, there were such differences for
total body fat, non-visceral, and visceral fat, as well as, liver fat
content. After adjustment for change in body weight, none of
these results remained statistically significant.






Age 60 ± 9 60 ± 9 n.s.
Sex (female) 64% 44% n.s.
Anthropometry
Weight [kg] 88.9 ± 14.2 90.2 ± 18.4 n.s.
Waist circumference [cm] 102.8 ± 10.1 103.9 ± 13.0 n.s.
Hip circumference [cm] 109.7 ± 12.5 108.6 ± 10.0 n.s.
WHR 0.94 ± 0.08 0.96 ± 0.09 n.s.
BIA—Body fat [%] 37.6 ± 9.5 35.6 ± 8.0 n.s.
Magnet resonance imaging and spectroscopy/Liver fat indices
Total body fat [L] 20.8 ± 6.9 20.1 ± 6.0 n.s.
Non-visceral fat [L] 15.7 ± 6.3 14.3 ± 5.0 n.s.
Visceral fat [L] 5.0 ± 1.3 5.8 ± 2.5 n.s.
Ratio of visceral and
subcutaneous fat [%]
26.2 ± 8.8 28.9 ± 10.1 n.s.
Liver fat content [%] 10.3 ± 7.1 11.1 ± 11.0 n.s.
Fatty liver index 65 ± 25 68 ± 29 n.s.
Glycemic metabolic outcomes
Fasting glucose [mg dl−1] 111.8 ± 10.8 109.8 ± 13.6 n.s.
2-h glucose [mg dl−1] 166.6 ± 30.2 175.2 ± 47.0 n.s.
HbA1c [%] 5.6 ± 0.3 5.7 ± 0.4 n.s.
Fasting insulin [mU L−1] 9.7 ± 5.3 10.7 ± 6.3 n.s.
Fasting C-peptide [µg L−1] 1.6 ± 0.6 2.0 ± 0.9 n.s.
HOMA-IR 2.7 ± 1.5 2.8 ± 2.1 n.s.
ISIffa 0.90 ± 0.34 0.87 ± 0.31 n.s.
Belfiore index 0.64 ± 0.19 0.68 ± 0.34 n.s.
HICc-peptide [mU µg
−1] 4.2 ± 1.5 4.9 ± 1.9 n.s.
Further metabolic outcomes
HDL cholesterol [mmol L−1] 1.3 ± 0.2 1.3 ± 0.3 n.s.
LDL cholesterol [mmol L−1] 3.7 ± 0.8 3.6 ± 0.7 n.s.
CRP [mg L−1] 5.0 ± 4.9 2.8 ± 2.7 n.s.
Leukocyte count [Gpt L−1] 5.85 ± 1.35 5.66 ± 1.73 n.s.
Uric acid [µmol L−1] 355 ± 63 360 ± 82 n.s.
Data are means (SD), significant differences between the groups: *p < 0.05, **p
< 0.01, ***p < 0.001.
When comparing the groups, we found a trendwise stronger
reduction in HbA1c in the fibre group (fibre: −0.1 ± 0.4% vs
placebo: 0.2 ± 0.5 µmol L−1; delta −0.3 ± 0.1 µmol L−1; p =
0.048; padj = 0.071), replicating results from our core paper.[9] We
also found a trend towards stronger reduction in uric acid lev-
els (fibre: −33 ± 38 µmol L−1 vs placebo: 0 ± 60 µmol L−1; delta
−33 ± 15 µmol L−1; p = 0.041; padj = 0.078), which was also seen
in our earlier publication.[9] However, the differences were not
statistically significant after adjustment for weight change.
When selecting patients fulfilling criteria for NAFLD at base-
line (liver fat content > 5.56%; n = 31), the trendwise effect on
liver fat was numerically stronger, but did not reach significance
either (fibre: −3.3 ± 6.7%-pts vs placebo: 0.1 ± 4.0%-pts.; delta
−3.4 ± 1.9%-pts.; p = 0.083).
Analysis by as-treated principles did not lead to relevantly
different results for any outcome. However, based on the as-
treated data set, a putative effect on liver fat as seen in our study
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Table 2. Baseline status and changes in lifestyle habits during intervention.
Fibre (n = 22) Placebo (n = 25) p-value
Total energy intake [kcal day−1] 2022 ± 460 2161 ± 699 n.s.
Carbohydrate intake [g day−1] 215 ± 58 242 ± 91 n.s.
Carbohydrate intake [kcal%] 44 ± 7 46 ± 8 n.s.
Fat intake [g day−1] 80 ± 22 85 ± 31 n.s.
Fat intake [kcal%] 37 ± 6 36 ± 6 n.s.
Protein intake [g day−1] 79 ± 23 85 ± 25 n.s.
Protein intake [kcal%] 16 ± 4 17 ± 3 n.s.
Dietary fibre intake [g 1000 kcal−1] 10 ± 2 11 ± 3 n.s.
Total dietary fibre intake [g day−1] 21 ± 5 23 ± 8 n.s.
insoluble 14 ± 3 15 ± 5 n.s.
soluble 6 ± 2 7 ± 2 n.s.
Magnesium [mg day−1] 336 ± 73 361 ± 108 n.s.
Calcium [mg day−1] 872 ± 230 951 ± 345 n.s.
Iron [mg day−1] 12 ± 3 12 ± 4 n.s.
Vitamin C [mg day−1] 134 ± 57 166 ± 70 n.s.
Vitamin D [µg day−1] 6 ± 5 6 ± 7 n.s.
Alcohol [g day−1] 15 ± 19 10 ± 16 n.s.
Change during one year
Total energy intake [kcal day−1] −134 ± 418 −126 ± 596 n.s.
Carbohydrate intake [g day−1] −2 ± 39 −13 ± 73 n.s.
Carbohydrate intake [kcal%] 3 ± 7 1 ± 7 n.s.
Fat intake [g day−1] −4 ± 29 −9 ± 29 n.s.
Fat intake [kcal%] 1 ± 8 −2 ± 5 n.s.
Protein intake [g day−1] −9 ± 18 4 ± 28 n.s.
Protein intake [kcal%] −1 ± 3 1 ± 3 n.s.
Dietary fibre intake [g 1000 kcal−1] 10 ± 4*** 2 ± 3* <0.001
Total dietary fibre intake [g day−1] 12 ± 9*** 1 ± 7 <0.001
Insoluble 12 ± 7*** 2 ± 5 <0.001
Soluble 1 ± 1* −0 ± 2 0.021
Magnesium [mg day−1] 2 ± 86 −8 ± 86 n.s.
Calcium [mg day−1] 33 ± 223 95 ± 386 n.s.
Iron [mg day−1] −2 ± 3 −0 ± 4 n.s.
Vitamin C [mg day−1] 12 ± 56 9 ± 54 n.s.
Vitamin D [µg day−1] −0 ± 9 −2 ± 7 n.s.
Alcohol [g day−1] −9 ± 22 −2 ± 11 n.s.
Data are means (SD). Nutrient intakes were calculated from four-day food records;
*Significant changes within the groups or differences between the groups: *p < 0.05,
**p < 0.01, ***p < 0.001.
(n= 19 subjects withNAFLD at baseline; fibre:−5.4± 8.0%-pts vs
placebo: 0.0 ± 5.2%-pts; delta −5.4 ± 3.0%-pts.; p = 0.090) could
be demonstrated in a new trial with 84 subjects (90% power).
4. Discussion
In our current analysis of OptiFiT, we find no conclusive evidence
for effects of insoluble cereal fibre on body fat distribution of liver
fat content. Mainly accountable to the limited sample size of the
small MR subgroup (in comparison to the entire cohort), both
metabolic outcomes such as HbA1c, postprandial glucose or uric
acid levels as well as MR-based assessed body fat compartments
and intrahepatic lipid storage failed to reach a statistically signif-
icant difference between the intervention groups.







Weight [kg] −3.7 ± 5.7** −1.8 ± 4.7** n.s. n.s.
Waist circumference [cm] −2.8 ± 5.6* −1.3 ± 5.1 n.s. n.s.
Hip circumference [cm] −2.3 ± 3.5** −0.7 ± 3.4 n.s. n.s.
WHR −0.01 ± 0.04 −0.01 ± 0.04 n.s. n.s.
BIA—Body fat [%] −1.9 ± 4.1 −1.6 ± 3.9 n.s. n.s.
Magnet resonance imaging and spectroscopy/Liver fat indices
Total body fat [L] −1.3 ± 2.8** −0.1 ± 2.2 0.041 n.s.
Non-visceral fat [L] −0.8 ± 2.1* 0.0 ± 1.5 0.039 n.s.
Visceral fat [L] −0.4 ± 0.7** −0.2 ± 0.9 0.019 n.s.
Ratio of visceral and
subcutaneous fat [%]
−0.5 ± 1.0* 0.1 ± 2.1 n.s. n.s.
Liver fat content [%] −1.5 ± 6.2 0.1 ± 3.4 0.035 n.s.
Fatty liver index −8 ± 17* −4 ± 12 n.s. n.s.
Glycemic metabolic
outcomes
Fasting glucose [mg dl−1] −4.7 ± 9.2* −3.0 ± 7.9 n.s. n.s.
2-h glucose [mg dl−1] −10.3 ± 35.6 −11.1 ± 40.7 n.s. n.s.
HbA1c [%] −0.1 ± 0.4 0.2 ± 0.5 0.048 n.s.
Fasting insulin [mU L−1] −2.3 ± 3.5** 0.0 ± 5.8 n.s. n.s.
Fasting C-peptide [µg L−1] −0.3 ± 0.5 0.1 ± 1.0 n.s. n.s.
HOMA-IR −0.7 ± 1.0** −0.1 ± 1.6 n.s. n.s.
ISIffa −0.14 ± 0.30 −0.12 ± 0.30 n.s. n.s.
Belfiore index 0.15 ± 0.18** 0.13 ± 0.26 n.s. n.s.
HICc-peptide [mU µg
−1] 1.1 ± 1.4* 1.1 ± 2.5 n.s. n.s.
Further metabolic outcomes
HDL cholesterol [mmol L−1 0.0 ± 0.2 −0.1 ± 0.2 n.s. n.s.
LDL cholesterol [mmol L−1] −0.2 ± 0.4* −0.1 ± 0.5 n.s. n.s.
CRP [mg L−1] −0.3 ± 4.0 −1.0 ± 2.4 n.s. n.s.
Leukocyte count [Gpt L−1] −0.46 ± 1.16 −0.02 ± 0.81 n.s. n.s.
Uric acid [µmol L−1] −33 ± 38** 0 ± 60 0.041 n.s.
Data are means (SD). *Significant changes within the groups or differences between
the groups: *p< 0.05, **p< 0.01, ***p< 0.001; Primary p-value fromMann–Whitney
test, adjusted p-value from ANOVA with weight change as co-variable.
Our study is the first human RCT investigating the effect of in-
soluble cereal fibre onmeasures of visceral adiposity andNAFLD.
While cohort studies consistently imply a role of non-digestible
carbohydrates in the prevention of NAFLD and the accumula-
tion of visceral fat,[15,16,18,19] RCTs in humans are still sparse and
weremainly using whole grain food products rather than specific
fibre supplements.[20] Several rodent trials indicate, that both in-
flammation and liver fat content could be reduced by interven-
tions with cellulose and other types of insoluble fibre.[17,21,22] Our
OptiFiT dataset encourages further interventional research in
humans.
Numerically, the reported difference in HbA1c is replicating
our earlier results from this trial, indicating that this subgroup is
representative for the entire cohort. Beneficial effects of whole-
grain products, in particular driven by insoluble fibre, have been
published in other studies, too.[32]
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In addition to that, we demonstrate a trendwise benefit for uric
acid, a common surrogate parameter for themetabolic syndrome
and in particular inflammation and NAFLD. This is mirrored
by a similar trend for visceral fat amount and liver fat content,
which remained completely unchanged in the placebo group
and seemed to decrease in the fibre group. This finding is in line
with our recent paper, showing that subjects with combined IFG
and IGT achieve stronger reductions in postprandial glucose
levels. Combined IFG-IGT is more tightly associated to obesity
and NAFLD when compared to isolated IGT.[33,34] It has to be
assumed, that better improvements of glycemia are related to a
phenotype-specific responsiveness, which could be connected
to either visceral obesity or hepatic fat storage. Other diabetes
prevention trials have demonstrated, that IFG-IGT subjects are
more responsive to lifestyle treatment or insulin-sensitizing
drugs that those with normal fasting glucose.[35–37] Lifestyle
treatments in general and insoluble fibre in particular seem
to primarily act via amelioration of insulin resistance rather
than beta-cell failure.[38,39] Our supplement—which was also
used in the previous ProFiMet study—also appears to affect
bile acid metabolism, which might provide another link to liver
function.[40] Anti-inflammatory effects of insoluble fibre were
also seen in earlier analyses of OptiFiT, corroborating findings
from association studies.[9,12,41,42]
We are of course aware of limitations of our study. The com-
bined intervention with lifestyle program and supplementation
may lead to combined effects, to differential changes in energy
intake, energy expenditure, and nutrient composition. We even
need to consider subjects in the placebo group with an unde-
sired high fibre intake, even though they just kept sticking to
the dietary recommendations apart from the supplement. How-
ever, both groups did not differ in any aspect of lifestyle changes,
including energy balance and diet composition. This covers all
macronutrients, dietary fibre from food (not the supplement) and
a selection of micronutrients, mirroring the intake of vegetables
and fruits, animal-based products and alcoholic beverages. De-
spite lacking a significantly different weight loss between fibre
and placebo, we adjusted our results for weight change. Most
subjects actually failed to increase their fibre intake by means
of regular diet as it is seen in earlier trials.[43] The majority of
our patients surpassed the desired level of insoluble fibers by
supplementation, only.[9,10] Similarly, the low-fat regime was not
followed as thoroughly as scheduled. Reducing fat intake below
30 kcal% is a typical goal in lifestyle intervention studies, but it
is rarely achieved for a long time.[1–4] As this flaw is apparent in
both of our intervention groups, we do not expect a modulating
impact on the fibre effect. With respect to our pedometer data, a
confounding effect of physical activity seems unplausible, as we
found no significant difference between the groups.
The sample size is very limited and—given the strict inclusion
criteria and the undesired skewed sex distribution—does not al-
low generalizable deductions for all prediabetes patients. Still, the
sample size is comparable to other pilot studies investigating the
effect of a single nutrient, supplement or food product on liver fat
content,[44–47] andmirrors the per-group sample sizes of previous
RCTs addressing other metabolic outcomes of supplementation
with insoluble cereal fibre.[38,48,49]
As for the previous publications of OpTiFiT, we are convinced
that using 4-day food records and drug accounting of supplement
tins was the best way to report dietary compliance, including
all sources of dietary fibre. Biomarkers for fibre intake are not
available.
In summary, we report no statistically significant effects of a
one-year intervention with twice-daily supplements containing
insoluble fibre on either glycometabolic or body fat distribution
in the MR subgroup of IGT subjects in OptiFiT. The numerical
effect size for HbA1c, uric acid, visceral fat volume, and liver fat
content warrants further targeted studies on poorly fermentable,
insoluble cereal fibre.
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